Alveo Technologies and Royal GD Expanded Partnership
The companies have agreed to broaden their collaboration to develop new molecular tests for livestock diseases.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you support prioritizing new diagnostic technology to improve livestock health and disease control?
Alveo Technologies and Royal GD have announced an expanded partnership agreement to advance animal health diagnostics. This extension follows a successful three-year collaboration that included the commercial deployment of an on-farm avian influenza test.
Why it matters
The partnership expansion aims to enable earlier disease detection and faster control measures within the agricultural sector. By utilizing new research and development resources, the companies intend to improve diagnostic capabilities for livestock health.
The companies have utilized their platform for 18 months to conduct on-farm testing for avian influenza. Future technical development will focus on creating molecular tests specifically designed for respiratory diseases in swine and cattle.
The players
Alveo Technologies
Alveo Technologies is a diagnostic company focused on developing molecular testing platforms for rapid disease detection.
Royal GD
Royal GD is an animal health organization that provides diagnostic services and veterinary expertise to the global agricultural industry.
The details
Royal GD will contribute new research and development resources to the Alveo platform to support the creation of advanced molecular testing tools. Concurrently, Alveo is growing its global distributor network to ensure producers have localized support for these diagnostic technologies.
Timeline
The original collaboration between the two companies began in September 2023.
Commercial deployment of their joint avian influenza test started in March 2025.
The expanded partnership agreement was officially announced on September 22, 2026.
The Tech Race
The expansion follows the industry trend of integrating the Alveo molecular testing platform into larger agricultural diagnostic workflows. This agreement marks a significant investment in the Alveo molecular testing platform to expand its application range beyond avian influenza.
Livestock producers can expect access to more robust diagnostic tools for early respiratory disease management in their herds. The expanded distributor network is designed to improve localized support and access to these molecular testing capabilities.
The takeaway
Early diagnostics for livestock remain a critical factor in maintaining global food security and animal health. As testing platforms become more localized, agricultural producers gain better control over potential outbreaks before they spread across wider operations.
Further reading
For more information on the latest innovations in animal health, visit the Biotech section.
Live Poll
Do you support prioritizing new diagnostic technology to improve livestock health and disease control?
